TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02146339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese n°1- cheese n°2 - cheese n°3
Description: Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese n°1- cheese n°3 - cheese n°2
Description: Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product

Intervention type: OTHER
Group type: OTHER
Intervention: cheese n°2 - cheese n°1- cheese n°3
Description: Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese n°2- cheese n°3 - cheese n°1
Description: Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese n°3 - cheese n°1- cheese n°2
Description: Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product

Intervention type: OTHER
Group type: OTHER
Intervention: Cheese n°3- cheese n°2 - cheese n°1
Description: Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
Study: NCT03353740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 labeled PSMA-11 PET
Description: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
Study: NCT02846220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Immunity to Change health coaching
Study: NCT03195400

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test
Description: The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
Study: NCT02184637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin + Piperaquine tetraphosphate
Description: White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin + Piperaquine tetraphosphate
Description: White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally
Study: NCT03613337

Intervention type: OTHER
Intervention: clinical restenosis
Description: The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.

Intervention type: OTHER
Intervention: clinical restenosis
Description: The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
Study: NCT01077596

Intervention type: DRUG
Intervention: Regular bupropion use
Description: Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Study: NCT02184637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether + Lumefantrine
Description: Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether + Lumefantrine
Description: Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally
Study: NCT01963494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic planning intervention
Description: Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual planning intervention
Description: Target persons form action plans on their own.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General motivational treatment
Description: Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
Study: NCT01077596

Intervention type: DRUG
Intervention: Regular SSRI (Selective serotonin reuptake inhibitors) use
Description: Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.

Intervention type: DRUG
Intervention: Regular TCA (Tricyclic antidepressants) use
Description: Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.

Intervention type: DRUG
Intervention: Regular use of any other antidepressant
Description: Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA.
Study: NCT01963494

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General motivational treatment
Description: Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General motivational treatment
Description: Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
Study: NCT04796519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Surgical procedure
Study: NCT02965157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART20
Study: NCT01551745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™ Vaccine
Description: Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
Study: NCT01652924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with facial mask
Description: This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual ventilation with facial mask
Description: This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist.
Study: NCT02413203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Blood and urine collections before and 3 hours after celecoxib administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blood and urine collections before and 3 hours after placebo administration.
Study: NCT03618641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
Study: NCT01851837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise time
Description: Continuous training, Interval training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise time
Description: Continuous training, Interval training
Study: NCT01105390

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rilotumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04420130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg iv every 3 weeks
Study: NCT03195400

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test
Description: The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperglycemic Clamp
Description: Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperglycemic Clamp
Description: Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.

Intervention type: DIAGNOSTIC_TEST
Intervention: Isoglycemic Intravenous Glucose Test
Description: Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.

Intervention type: DIAGNOSTIC_TEST
Intervention: Isoglycemic Intravenous Glucose Test
Description: Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperinsulinemic Euglycemic Clamp and 2H20
Description: Test is used to assess insulin effects on hepatic glucose production.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperinsulinemic Euglycemic Clamp and 2H20
Description: Test is used to assess insulin effects on hepatic glucose production.
Study: NCT04420130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
Study: NCT03302364

Intervention type: DRUG
Intervention: Risperidone
Description: patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
Study: NCT04363190

Intervention type: DIAGNOSTIC_TEST
Intervention: Cytogenetic analysis
Description: 1. FISH study using the UroVysion kit in interphase peripheral lymphocytes, that allows the study of numerical aberrations for chromosomes 3, 7 and 17 and locus 9p21.~2. G banding study to analyse the whole karyotype study regarding both numerical and structural aberrations during metaphase.~3. Sister chromatid exchanges (SCE) analysis with bromodeoxyuridine (BrdU) staining for the whole karyotype during metaphase: analizing the proportion of SCE per metaphase (NSM).

Intervention type: DIAGNOSTIC_TEST
Intervention: Cytogenetic analysis
Description: 1. FISH study using the UroVysion kit in interphase peripheral lymphocytes, that allows the study of numerical aberrations for chromosomes 3, 7 and 17 and locus 9p21.~2. G banding study to analyse the whole karyotype study regarding both numerical and structural aberrations during metaphase.~3. Sister chromatid exchanges (SCE) analysis with bromodeoxyuridine (BrdU) staining for the whole karyotype during metaphase: analizing the proportion of SCE per metaphase (NSM).
Study: NCT03351101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon C
Description: Senofilcon C Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samfilcon A
Description: Samfilcon A Contact Lens
Study: NCT00222131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg QD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03095196

Intervention type: DEVICE
Intervention: Multipolar CRT-d, plus conventional drug therapy for HF.
Description: A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.

Intervention type: DEVICE
Intervention: Bipolar CRT-d, plus conventional drug therapy for HF.
Description: A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.

Intervention type: DRUG
Intervention: HF drugs
Description: full medical therapy to treat HF symptoms and its progression.
Study: NCT04420130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: First give pancreatic cancer patients with liver metastases to ablation of liver metastases
Study: NCT03475212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virus Specific T-cell (VST) infusion
Description: Patients will receive partially HLA-matched VSTs as a single infusion. Patients who have a partial response (\>1 log decrease in viral load without clearance) or no response and do not have treatment-related dose-limiting toxicities are eligible to receive up to 3 additional doses from day 30 after the initial infusion and at 2 weekly intervals thereafter. The viral load of the virus (or viruses) that patients are initially treated for are monitored by viral PCR.
Study: NCT05685940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient questionnaires
Description: The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
Study: NCT01784796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: 8 week Mindfulness Based Stress Reduction Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: 8 week Health Education Program
Study: NCT03095196

Intervention type: DRUG
Intervention: HF drugs
Description: full medical therapy to treat HF symptoms and its progression.
Study: NCT02257801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional beverage fortified with 6mg lutein/day
Description: 2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional beverage fortified with 12mg lutein/day
Description: 2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional beverage fortified with 12mg lutein/day
Description: 2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
Study: NCT03708393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imagio (IUS+OA)
Description: The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imagio Ultrasound
Description: Imagio ultrasound images to be reviewed as part of the reader study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Mammography images as available per standard of care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography
Description: Mammography images as available per standard of care
Study: NCT00839176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100
Description: Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100
Description: Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100
Description: Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RX-10100
Description: Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
Study: NCT03881761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20 bispecific CAR-T cells
Description: collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg
Study: NCT03425474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Initial dose plus supplemental doses as necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Initial dose plus supplemental doses as necessary
Study: NCT04333303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a complex regional Advance Care Planning program
Description: Sustainable implementation of ACP at micro- (qualification of professional ACP facilitators to lead conversations in cooperation with family physicians), meso- (qualification of relevant co-actors, organisational development of participating institutions) and macro-level (regional ACP steering group and network), ensuring that valid ACP is encouraged, facilitated, documented, known and honored.~Core of the intervention is a modular 9-day-training for ACP facilitators. These will be preferably located in regional pools, serving more than one nursing home, and reimbursed, if certified, by German sickness funds based on recent legislation (§ 132g Social Code Book \[SGB\] V: 1 full-time facilitator for 400 residents). ACP conversations will be offered to all residents. Regional intervention at meso- and macro-level comprises various formats of specific ACP training and information for leadership and staff, and aims to support professional change management.
Study: NCT04486001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSC-04
Description: adipose stem cells derived from screened donor lipoaspirate and culture expanded.
Study: NCT04609007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: A brief 4 sessions online CBT program with therapist support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular help-line telephone counselling
Description: A single session of telephone counselling with a help-line counsellor
Study: NCT02423967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplant uses frozen anonymous stool
Description: The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Transplant uses fresh familial stool
Description: The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
Study: NCT00648050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride Extended-Release Capsules, 300 mg
Description: 300mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verelan® PM Extended-Release Capsules, 300 mg
Description: 300mg, single dose fasting